May 14th 2024
The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
What Employers Can Do to Stand Up for Biosimilar Formulary Placement
February 24th 2022A report from the National Alliance of Healthcare Purchaser Coalitions detailed the common concerns employers have regarding implementing biosimilars within their health care plans and outlined how they could take charge and make a difference.
Biosimilars CEOs: Opportunities Abound, but Regulatory, “Branding” Hurdles Remain
February 24th 2022There remains risk in the US market due to regulatory and legal hurdles—not to mention a combative political environment, according to executives who gathered last week during the “CEOs Unplugged” session at Access! 2022, held by the Association for Accessible Medicines (AAM) in Orlando.
CMS Seeks Answers for Slower-Than-Expected Biosimilar Adoption, Rawal Says
February 21st 2022Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, spoke during the Association for Accessible Medicines' Access! annual meeting, which gathered in Orlando, Florida, February 15-16.
Experts Call for More Regulatory Action to Address Biosimilar Interchangeability Confusion
February 17th 2022A panel of experts details the current concerns regarding interchangeability designations for biosimilars in the United States and calls for regulators and policy makers to make changes to allow to easier access to biosimilars and greater adoption.
The Biosimilars Forum's Julie Reed Shares Her Major Goals for the Organization in New Role
February 13th 2022Improving access and getting big legislative changes for biosimilars passed are just some of the many plans that Julie M. Reed, the new executive director of the Biosimilars Forum, has for the organization.
The Biosimilars Forum Announces Julie Reed as New Executive Director
January 31st 2022The non-profit organization dedicated to the advancement of biosimilars has appointed Cofounder and President Juliana (Julie) M. Reed, as the new executive director. Reed shared some of her goals for the Biosimilars Forum in an interview with The Center for Biosimilars®.
Wayne Winegarden, PhD: How to Ensure Biosimilar Affordability as Reference Drug Prices Increase
January 30th 2022Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute, discusses how to ensure affordability of adalimumab biosimilars when they enter the market as AbbVie continues to raise the price of the reference product (Humira).
Robert Popovian, PharmD, MS, Discusses Biosimilar Progress and Education in the United States
January 12th 2022As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.